A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular outcomes
The DOI matches its Crossref record; 60 of the 61 references it cites were found in a registry or an index.
Abstract
Background: The comparative effects of statins, ezetimibe with or without statins and proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors remain unassessed. Design: Bayesian network meta-analysis was conducted to compare treatment groups. Methods: Thirty-nine randomized controlled trials were selected using MEDLINE, EMBASE, and CENTRAL (inception – September 2017). Results: In network meta-analysis of 189,116 patients, PCSK9 inhibitors were ranked as the best treatment for prevention of major adverse cardiovascular events (Surface Under Cumulative Ranking Curve (SUCRA), 85%), myocardial infarction (SUCRA, 84%) and stroke (SUCRA, 80%). PCSK9 inhibitors reduced the risk of major adverse cardiovascular events compared with ezetimibe + statin (odds ratio (OR): 0.72; 95% credible interval (CrI), 0.55–0.95; Grading of Recommendation Assessment, Development and Evaluation (GRADE) criteria: moderate), statin (OR: 0.78; 95% CrI: 0.62–0.97; GRADE: moderate) and placebo (OR: 0.63; 95% CrI: 0.49–0.79; GRADE: high). The PCSK9 inhibitors were consistently superior to groups for major adverse cardiovascular event reduction in secondary prevention trials (SUCRA, 95%). Statins had the highest probability of having lowest rates of all-cause mortality (SUCRA, 82%) and cardiovascular mortality (SUCRA, 84%). Compared with placebo, statins reduced the risk of all-cause mortality (OR: 0.88; 95% CrI: 0.83–0.94; GRADE: moderate) and cardiovascular mortality (OR: 0.84; 95% CrI: 0.77–0.90; GRADE: high). For cardiovascular mortality, PCSK9 inhibitors were ranked as the second best treatment (SUCRA, 78%) followed by ezetimibe + statin (SUCRA, 50%). Conclusion: PCSK9 inhibitors were ranked as the most effective treatment for reducing major adverse cardiovascular events, myocardial infarction and stroke, without having major safety concerns. Statins were ranked as the most effective therapy for reducing mortality.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In clinical trials, the frequency of proteinuria is generally low and, in most cases, is not higher than for placebo [256].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [256]
Citations
Cites
The Cochrane Collaboration's tool for assessing risk of bias in randomised trials
Higgins, J. P. T., Altman, D. G., Gotzsche, P. C., Juni, P., Moher, D., Oxman, A. D., Savovic, J., Schulz, K. F., Weeks, L., Sterne, J. A. C., et al. (2011) · BMJ · doi:10.1136/bmj.d5928 · Cited by 33,817
Shamseer, L., Moher, D., Clarke, M., Ghersi, D., Liberati, A., Petticrew, M., Shekelle, P., Stewart, L. A., & the PRISMA-P Group (2015) · BMJ · doi:10.1136/bmj.g7647 · Cited by 13,120
Hutton, B., Salanti, G., Caldwell, D. M., Chaimani, A., Schmid, C. H., Cameron, C., Ioannidis, J. P. A., Straus, S., Thorlund, K., Jansen, J. P., et al. (2015) · Annals of Internal Medicine · doi:10.7326/m14-2385 · Cited by 8,269 · cited 1×
“This NMA is performed according to the Cochrane Collaboration guidelines(7) and is reported in accordance with Preferred Reporting Items for Systematic Reviews and Meta-Analysis Extension (PRISMA) statement for systematic reviews incorporating network meta-analyses for health care interventions.(8,9)”
MethodPrevention of Coronary Heart Disease with Pravastatin in Men with Hypercholesterolemia
Shepherd, J., Cobbe, S. M., Ford, I., Isles, C. G., Lorimer, A. R., Macfarlane, P. W., McKillop, J. H., & Packard, C. J. (1995) · New England Journal of Medicine · doi:10.1056/nejm199511163332001 · Cited by 7,449
Sacks, F. M., Pfeffer, M. A., Moye, L. A., Rouleau, J. L., Rutherford, J. D., Cole, T. G., Brown, L., Warnica, J. W., Arnold, J. M. O., Wun, C.-C., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199610033351401 · Cited by 7,439
Stone, N. J., Robinson, J. G., Lichtenstein, A. H., Bairey Merz, C. N., Blum, C. B., Eckel, R. H., Goldberg, A. C., Gordon, D., Levy, D., Lloyd-Jones, D. M., et al. (2014) · Circulation · doi:10.1161/01.cir.0000437738.63853.7a · Cited by 7,081
Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein
Ridker, P. M., Danielson, E., Fonseca, F. A. H., Genest, J., Gotto, A. M., Kastelein, J. J. P., Koenig, W., Libby, P., Lorenzatti, A. J., MacFadyen, J. G., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0807646 · Cited by 6,674
Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
Sabatine, M. S., Giugliano, R. P., Keech, A. C., Honarpour, N., Wiviott, S. D., Murphy, S. A., Kuder, J. F., Wang, H., Liu, T., Wasserman, S. M., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1615664 · Cited by 6,138 · cited 1×
“However, former reports have shown that major adverse cardiovascular event (MACE) reduction was considerably lower than expected in response to profound reductions in LDL-C by PCSK9 inhibitors.(4,6) This lack of linear correlation between LDL-C reduction and MACE reduction may have occurred due to small study effects…”
Result(1998) · New England Journal of Medicine · doi:10.1056/nejm199811053391902 · Cited by 5,261
Downs, J. R., Clearfield, M., Weis, S., Whitney, E., Shapiro, D. R., Beere, P. A., Langendorfer, A., Stein, E. A., Kruyer, W., Gotto, Jr., et al. (1998) · JAMA · doi:10.1001/jama.279.20.1615 · Cited by 5,236
Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes
Cannon, C. P., Blazing, M. A., Giugliano, R. P., McCagg, A., White, J. A., Theroux, P., Darius, H., Lewis, B. S., Ophuis, T. O., Jukema, J. W., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1410489 · Cited by 4,487 · cited 2×
“The IMProved Reduction of Outcomes: Vytorin Efficacy International Trial showed that the incremental 20–25% reduction in LDL-C achieved by adding ezetimibe to statins yielded the expected cardiovascular benefits.(3) On the other hand, various pooled analyses had shown that PCSK9 inhibitors provided more robust reducti…”
BackgroundStone, N. J., Robinson, J. G., Lichtenstein, A. H., Bairey Merz, C. N., Blum, C. B., Eckel, R. H., Goldberg, A. C., Gordon, D., Levy, D., Lloyd-Jones, D. M., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.11.002 · Cited by 3,845
Salanti, G., Ades, A. E., & Ioannidis, J. P. A. (2011) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2010.03.016 · Cited by 3,766 · cited 1×
“‘‘Rankograms’’ with surface under the cumulative ranking curve (SUCRA) were reported to provide a comparative hierarchy of efficacy and safety of the treatment groups.(16) A SUCRA is a numerical representation of the probability of effectiveness or safety, that is, a SUCRA of 90% means the treatment of interest has ac…”
BackgroundColhoun, H. M., Betteridge, D. J., Durrington, P. N., Hitman, G. A., W Neil, H. A., Livingstone, S. J., Thomason, M. J., Mackness, M. I., Charlton-Menys, V., & Fuller, J. H. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16895-5 · Cited by 3,755
Rosuvastatin to Prevent Vascular Events in Men and Women With Elevated C-Reactive Protein
Ridker, P. M., Danielson, E., Fonseca, F. A. H., Genest, J., Gotto, A. M., Kastelein, J. J. P., Koenig, W., Libby, P., Lorenzatti, A. J., MacFadyen, J. G., et al. (2009) · Obstetrical & Gynecological Survey · doi:10.1097/01.ogx.0000344393.60303.0a · Cited by 3,641
Shepherd, J., Blauw, G. J., Murphy, M. B., Bollen, E. L., Buckley, B. M., Cobbe, S. M., Ford, I., Gaw, A., Hyland, M., Jukema, J. W., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)11600-x · Cited by 3,378
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
Catapano, A. L., Graham, I., De Backer, G., Wiklund, O., Chapman, M. J., Drexel, H., Hoes, A. W., Jennings, C. S., Landmesser, U., Pedersen, T. R., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw272 · Cited by 3,162
PEDERSEN, T. R. (2004) · Atherosclerosis Supplements · doi:10.1016/j.atherosclerosissup.2004.08.027 · Cited by 3,106
High-Dose Atorvastatin after Stroke or Transient Ischemic Attack
The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061894 · Cited by 2,887
Baigent, C., Landray, M. J., Reith, C., Emberson, J., Wheeler, D. C., Tomson, C., Wanner, C., Krane, V., Cass, A., Craig, J., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60739-3 · Cited by 2,479
Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events
Robinson, J. G., Farnier, M., Krempf, M., Bergeron, J., Luc, G., Averna, M., Stroes, E. S., Langslet, G., Raal, F. J., El Shahawy, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501031 · Cited by 2,296
Combination of direct and indirect evidence in mixed treatment comparisons
Lu, G., & Ades, A. E. (2004) · Statistics in Medicine · doi:10.1002/sim.1875 · Cited by 2,166 · cited 2×
“The inconsistency of the model was calculated as suggested by Lu and Ades.13 We obtained a median estimate of odds ratio (OR) from the posterior distribution and reported it with 2.5th to the 97.5th centiles of the distribution (95% credible interval (CrI)).”
MethodRosuvastatin and Cardiovascular Events in Patients Undergoing Hemodialysis
Fellström, B. C., Jardine, A. G., Schmieder, R. E., Holdaas, H., Bannister, K., Beutler, J., Chae, D.-W., Chevaile, A., Cobbe, S. M., Grönhagen-Riska, C., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810177 · Cited by 2,036
Puhan, M. A., Schunemann, H. J., Murad, M. H., Li, T., Brignardello-Petersen, R., Singh, J. A., Kessels, A. G., Guyatt, G. H., & for the GRADE Working Group (2014) · BMJ · doi:10.1136/bmj.g5630 · Cited by 1,812
Intensive Lipid Lowering with Simvastatin and Ezetimibe in Aortic Stenosis
Rossebø, A. B., Pedersen, T. R., Boman, K., Brudi, P., Chambers, J. B., Egstrup, K., Gerdts, E., Gohlke-Bärwolf, C., Holme, I., Kesäniemi, Y. A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0804602 · Cited by 1,644
Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events
Sabatine, M. S., Giugliano, R. P., Wiviott, S. D., Raal, F. J., Blom, D. J., Robinson, J., Ballantyne, C. M., Somaratne, R., Legg, J., Wasserman, S. M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500858 · Cited by 1,509
Rosuvastatin in older patients with systolic heart failure
Kjekshus, J., Apetrei, E., Barrios, V., Böhm, M., Cleland, J. G. F., Cornel, J. H., Dunselman, P., Fonseca, C., Goudev, A., Grande, P., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa0706201 · Cited by 1,487
Silverman, M. G., Ference, B. A., Im, K., Wiviott, S. D., Giugliano, R. P., Grundy, S. M., Braunwald, E., & Sabatine, M. S. (2016) · JAMA · doi:10.1001/jama.2016.13985 · Cited by 1,483 · cited 4×
“Email: safinmc@gmail.com 1mmol/L reduction in LDL-C.2 The addition of ezetimibe to statin therapy can result in additional LDL-C reduction accompanied by exponential cardiovascular risk reduction.3 Similarly, PCSK9 inhibitors have shown to generate incremental reductions in LDL-C compared with ezetimibe or placebo.4,5…”
BackgroundMethodInfluentialGISSI-HF investigators (2008) · The Lancet · doi:10.1016/s0140-6736(08)61240-4 · Cited by 1,106
Holdaas, H., Fellström, B., Jardine, A. G., Holme, I., Nyberg, G., Fauchald, P., Grönhagen-Riska, C., Madsen, S., Neumayer, H.-H., Cole, E., et al. (2003) · The Lancet · doi:10.1016/s0140-6736(03)13638-0 · Cited by 919
Cholesterol Lowering in Intermediate-Risk Persons without Cardiovascular Disease
Yusuf, S., Bosch, J., Dagenais, G., Zhu, J., Xavier, D., Liu, L., Pais, P., López-Jaramillo, P., Leiter, L. A., Dans, A., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1600176 · Cited by 848
Turner, R. M., Davey, J., Clarke, M. J., Thompson, S. G., & Higgins, J. P. (2012) · International Journal of Epidemiology · doi:10.1093/ije/dys041 · Cited by 837 · cited 1×
“40).(14) Markov chain Monte Carlo (MCMC) modeling was used to estimate the relative ranking probability of each treatment group.”
MethodA 52-Week Placebo-Controlled Trial of Evolocumab in Hyperlipidemia
Blom, D. J., Hala, T., Bolognese, M., Lillestol, M. J., Toth, P. D., Burgess, L., Ceska, R., Roth, E., Koren, M. J., Ballantyne, C. M., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1316222 · Cited by 720
Serruys, P. W. J. C. (2002) · JAMA · doi:10.1001/jama.287.24.3215 · Cited by 719
Crouse, J. R., Raichlen, J. S., Riley, W. A., Evans, G. W., Palmer, M. K., O’Leary, D. H., Grobbee, D. E., Bots, M. L., & METEOR Study Group, F. T. (2007) · JAMA · doi:10.1001/jama.297.12.1344 · Cited by 708
Knopp, R. H., d’Emden, M., Smilde, J. G., Pocock, S. J., & on behalf of the ASPEN Study Group (2006) · Diabetes Care · doi:10.2337/dc05-2415 · Cited by 550
Kastelein, J. J. P., Ginsberg, H. N., Langslet, G., Hovingh, G. K., Ceska, R., Dufour, R., Blom, D., Civeira, F., Krempf, M., Lorenzato, C., et al. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehv370 · Cited by 533
Cognitive function in a randomized trial of evolocumab
Giugliano, R. P., Mach, F., Zavitz, K., Kurtz, C., Im, K., Kanevsky, E., Schneider, J., Wang, H., Keech, A., Pedersen, T. R., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1701131 · Cited by 492
Moriarty, P. M., Thompson, P. D., Cannon, C. P., Guyton, J. R., Bergeron, J., Zieve, F. J., Bruckert, E., Jacobson, T. A., Kopecky, S. L., Baccara-Dinet, M. T., et al. (2015) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2015.08.006 · Cited by 470
Cannon, C. P., Cariou, B., Blom, D., McKenney, J. M., Lorenzato, C., Pordy, R., Chaudhari, U., & Colhoun, H. M. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehv028 · Cited by 402
Kereiakes, D. J., Robinson, J. G., Cannon, C. P., Lorenzato, C., Pordy, R., Chaudhari, U., & Colhoun, H. M. (2015) · American Heart Journal · doi:10.1016/j.ahj.2015.03.004 · Cited by 349
Koren, M. J., & Hunninghake, D. B. (2004) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2004.07.053 · Cited by 280
Lipinski, M. J., Benedetto, U., Escarcega, R. O., Biondi-Zoccai, G., Lhermusier, T., Baker, N. C., Torguson, R., Brewer, H. B., & Waksman, R. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehv563 · Cited by 256 · cited 6×
“Seventh, we did not assess the LDL-C lowering potential of the treatment groups as this aspect has been extensively studied in prior meta-analyses.(4,5,52,57) Eight, we did not perform cost effective analysis of these agents and since cost effectiveness of PCSK9 inhibitors based on their LDL-C lowering potential is an…”
MethodResultInfluentialRoth, E. M., Taskinen, M.-R., Ginsberg, H. N., Kastelein, J. J. P., Colhoun, H. M., Robinson, J. G., Merlet, L., Pordy, R., & Baccara-Dinet, M. T. (2014) · International Journal of Cardiology · doi:10.1016/j.ijcard.2014.06.049 · Cited by 249
Ginsberg, H. N., Rader, D. J., Raal, F. J., Guyton, J. R., Baccara-Dinet, M. T., Lorenzato, C., Pordy, R., & Stroes, E. (2016) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-016-6685-y · Cited by 214
PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease
Schmidt, A. F., Pearce, L. S., Wilkins, J. T., Overington, J. P., Hingorani, A. D., & Casas, J. P. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011748.pub2 · Cited by 205 · cited 3×
“However, the EBBINGHAUS study(56) and a more recent meta-analysis by Schmidt et al.(57) have not demonstrated PCSK9 inhibitor-related neurocognitive concerns at extended follow-up duration, which advocates the long-term safety of these agents.”
MethodBarton, P., Andronis, L., Briggs, A., McPherson, K., & Capewell, S. (2011) · BMJ · doi:10.1136/bmj.d4044 · Cited by 195 · cited 1×
“Cardiovascular disease (CVD) is a leading cause of morbidity and mortality worldwide.(1) Statins, ezetimibe and proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors have been proven to be beneficial in reducing CVD risk by decreasing low-density lipoprotein cholesterol (LDL-C).”
BackgroundFarnier, M., Jones, P., Severance, R., Averna, M., Steinhagen-Thiessen, E., Colhoun, H. M., Du, Y., Hanotin, C., & Donahue, S. (2016) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2015.11.010 · Cited by 189
Updated Cost-effectiveness Analysis of PCSK9 Inhibitors Based on the Results of the FOURIER Trial
Kazi, D. S., Penko, J., Coxson, P. G., Moran, A. E., Ollendorf, D. A., Tice, J. A., & Bibbins-Domingo, K. (2017) · JAMA · doi:10.1001/jama.2017.9924 · Cited by 146
Roth, E. M., Moriarty, P. M., Bergeron, J., Langslet, G., Manvelian, G., Zhao, J., Baccara-Dinet, M. T., & Rader, D. J. (2016) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2016.08.043 · Cited by 127
Landray, M., Baigent, C., Leaper, C., Adu, D., Altmann, P., Armitage, J., Ball, S. T., Baxter, A., Blackwell, L. S., Cairns, H., et al. (2006) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2005.11.018 · Cited by 107
Stroes, E., Guyton, J. R., Lepor, N., Civeira, F., Gaudet, D., Watts, G. F., Baccara‐Dinet, M. T., Lecorps, G., Manvelian, G., Farnier, M., et al. (2016) · Journal of the American Heart Association · doi:10.1161/jaha.116.003421 · Cited by 102
Toth, P. P., Worthy, G., Gandra, S. R., Sattar, N., Bray, S., Cheng, L., Bridges, I., Worth, G. M., Dent, R., Forbes, C. A., et al. (2017) · Journal of the American Heart Association · doi:10.1161/jaha.116.005367 · Cited by 92 · cited 5×
“Seventh, we did not assess the LDL-C lowering potential of the treatment groups as this aspect has been extensively studied in prior meta-analyses.(4,5,52,57) Eight, we did not perform cost effective analysis of these agents and since cost effectiveness of PCSK9 inhibitors based on their LDL-C lowering potential is an…”
InfluentialBayesian estimation in random effects meta‐analysis using a non‐informative prior
Bodnar, O., Link, A., Arendacká, B., Possolo, A., & Elster, C. (2017) · Statistics in Medicine · doi:10.1002/sim.7156 · Cited by 73 · cited 1×
“model (informative priors).(12) For all estimates, convergence was achieved at 40,000 iterations and autocorrelation was checked and confirmed.”
BackgroundKhan, A. R., Bavishi, C., Riaz, H., Farid, T. A., Khan, S., Atlas, M., Hirsch, G., Ikram, S., & Bolli, R. (2017) · Circulation: Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.116.003153 · Cited by 72
Self-citationEfficacy and Tolerability of Lovastatin in 3390 Women with Moderate Hypercholesterolemia
Bradford, R. H., Downton, M., Chremos, A. N., Langendorfer, A., Stinnett, S. S., Nash, D. T., Mantell, G., & Shear, C. L. (1993) · Annals of Internal Medicine · doi:10.7326/0003-4819-118-11-199306010-00004 · Cited by 39
Kouvelos, G. N., Arnaoutoglou, E. M., Matsagkas, M. I., Kostara, C., Gartzonika, C., Bairaktari, E. T., & Milionis, H. J. (2013) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/1074248412445506 · Cited by 35
Larjo, A., & Lähdesmäki, H. J. (2015) · EURASIP Journal on Bioinformatics and Systems Biology · doi:10.1186/s13637-015-0024-7 · Cited by 20 · cited 1×
“Markov chain Monte Carlo (MCMC) modeling was used to estimate the relative ranking probability of each treatment group.(15) ‘‘Rankograms’’ with surface under the cumulative ranking curve (SUCRA) were reported to provide a comparative hierarchy of efficacy and safety of the treatment groups.”
Method
Research works printed but not linked: 6
- Toth PP, 2017, J Am Heart Assoc, 6
- Kastelein JJ, 2015, Eur Heart J, 36, 2996
- Koren MJ, 2004, J Am Coll Cardiol, 44, 1772
- Stroes E, 2016, J Am Heart Assoc, 5
- Khan AR, 2017, Circ Cardiovasc Qual Outcomes, 10
- Schmidt AF, 2017, Cochrane Database Syst Rev, 4, Cd011748
Cited by
Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz455 · Cited by 8,961
Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2019) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2019.08.014 · Cited by 4,854
“Taken together with other studies,(271) IMPROVE-IT supports the proposal that ezetimibe should be used as second-line therapy in association with statins when the therapeutic goal is not achieved at the maximal tolerated statin dose, or in cases where a statin cannot be prescribed.(272,273)”
Primary prevention of cardiovascular disease: A review of contemporary guidance and literature
Stewart, J., Manmathan, G., & Wilkinson, P. (2017) · JRSM Cardiovascular Disease · doi:10.1177/2048004016687211 · Cited by 464
Cardiovascular disease in type 2 diabetes mellitus: progress toward personalized management
Ma, C.-X., Ma, X.-N., Guan, C.-H., Li, Y.-D., Mauricio, D., & Fu, S.-B. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01516-6 · Cited by 464
The link between diabetes and atherosclerosis
La Sala, L., Prattichizzo, F., & Ceriello, A. (2019) · European Journal of Preventive Cardiology · doi:10.1177/2047487319878373 · Cited by 236
“However, the ability of statins to reduce major cardiovascular events and mortality outweighs this risk, and no change in clinical practice is currently recommended.(23,24) Besides these benefits in reducing cardiovascular mortality and reducing hyperlipidaemia (the latter stimulating for vascular calcification (VC)),…”
Background
Metadata
- Authors
- Khan, S. U., Talluri, S., Riaz, H., Rahman, H., Nasir, F., Bin Riaz, I., Sattur, S., Ahmed, H., Kaluski, E., & Krasuski, R.
- Affiliations
- Guthrie Robert Packer Hospital (US)
- Cleveland Clinic (US)
- Mayo Clinic, Rochester, MN, USA
- Duke University (US)
- Corresponding author
- Khan, Safi U
- Venue
- European Journal of Preventive Cardiology
- Publisher
- Oxford University Press (OUP)
- Published
- 2018-03-23
- Volume
- 25
- Issue
- 8
- Pages
- 844-853
- ISSN
- 2047-4873 (ISSN-L)
- 2047-4881
- OpenAlex
- W2789251847
- Cited by
- 61
- References
- 61
- Citations by year
- 2026: 2 · 2025: 5 · 2024: 9 · 2023: 9 · 2022: 10 · 2021: 4 · 2020: 8 · 2019: 11 · 2018: 1
- FWCI
- 1.33
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
- Locations
- European Journal of Preventive Cardiology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Acute Myocardial Infarction Research
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Antiplatelet Therapy and Cardiovascular Diseases
- Keywords
- PCSK9 inhibitors, statins, ezetimibe, major adverse cardiovascular events, myocardial infarction, stroke, cardiovascular mortality, all-cause mortality, hypercholesterolemia, secondary prevention, lipid-lowering therapy, treatment ranking, SUCRA ranking, GRADE quality of evidence, cost-effectiveness, quality of life
- MeSH terms
- Ezetimibe, Proprotein Convertase 9, PCSK9 Inhibitors, Aged, Anticholesteremic Agents, Bayes Theorem, Cardiovascular Diseases, Drug Therapy, Combination, Female, Humans, Lipids, Male, Middle Aged, Biomarkers, Serine Proteinase Inhibitors, Randomized Controlled Trials as Topic, Treatment Outcome, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Dyslipidemias
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.